View Clinical Trial (Medical Research Study)
The Birt Hogg-Dube Syndrome: Identification of the Disease Gene and Characterization of the Predisposition of Renal Cancer
| City: |
|
Bethesda |
| State: |
|
Maryland |
| Zip Code: |
|
20892 |
| Conditions: |
|
Syndrome |
| Purpose: |
|
This study will investigate the genetic cause of Birt Hogg-Dube (BHD) syndrome and the
relationship of this disorder to kidney cancer. BHD is a rare inherited condition
characterized by papules, or bumps-benign tumors involving hair follicles-on the head and
neck. People with BHD are at increased risk of developing kidney cancer. Scientists have
identified the chromosome (strand of genetic material in the cell nucleus) that contains the
BHD gene and the region of the gene on the chromosome. This study will try to learn more
about:
- The characteristics and type of kidney tumors associated with BHD
- The risk of kidney cancer in people with BHD
- Whether more than one gene causes BHD
- The genetic mutations (changes) responsible for BHD
Patients with known or suspected Birt Hogg-Dube syndrome, and their family members, may be
eligible for this study. Candidates will be screened with a family history and review of
medical records, including pathology reports for tumors, and films of computed tomography
(CT) and magnetic resonance imaging (MRI) scans.
Participants may undergo various tests and procedures, including the following:
- Physical examination
- Review of personal and family history with a cancer doctor, cancer nurses, kidney
surgeon, and genetic counselor
- Chest and other x-rays
- Ultrasound (imaging study using sound waves)
- MRI (imaging study using radiowaves and a magnetic field)
- CT scans of the chest and abdomen (imaging studies using radiation)
- Blood tests for blood chemistries and genetic testing
- Skin evaluation, including a skin biopsy (surgical removal of a small skin tissue
sample for microscopic evaluation)
- Cheek swab or mouthwash to collect cells for genetic analysis
- Lung function studies
- Medical photography of skin lesions
These tests will be done on an outpatient basis in either one day or over 3 to 4 days. When
the studies are complete, participants will receive counseling about the findings and
recommendations. Patients with kidney lesions may be asked to return periodically, such as
every 3 to 36 months, based on their individual condition, to document the rate of
progression of the lesions.
...
|
| Study Summary: |
|
Background
- BHD is a rare, autosomal dominantly inherited disorder which confers susceptibility to
develop multifocal, bilateral renal cancer, spontaneous pneumothorax and
fibrofolliculomas.
- BHD is caused by mutations in the BHD gene located on Chromosome17p11.2.
- Defining the genetic and biochemical pathways leading to renal tumorigenesis in BHD may
lead to the development of new molecularly targeted drugs.
Objectives
- To define the types and characteristics (including patterns of growth) of renal cancer
associated with BHD.
- To determine the risk of renal cancer, lung cysts and fibrofollicullomas in patients
with BHD.
- To define the natural history of BHD related renal tumors.
- To determine if other genes contribute to BHD.
- Identify genotype / phenotype correlations.
Eligibility
- Patients with histologically confirmed fibrofolliculomas.
- Patients with clinical evidence of multiple skin papules consistent with
fibrofolliculomas, and a family history of spontaneous pneumothorax or kidney cancer.
- A relative of a patient with a confirmed diagnosis of BHD.
- Patients with a known germline BHD mutation.
Design
- These rare families will be recruited to genetically confirm diagnosis, determine size
and location of renal tumors, size at presentation, growth rate and metastatic
potential of renal tumors.
- Genetic testing will be offered to gain appreciation of the effect of mutations the BHD
gene and to assess the relative activity of various germline and somatic mutations.
- We will determine if there is a relationship between mutation and disease phenotype.
|
| Criteria: |
|
- INCLUSION CRITERIA:
Patients with known or suspected Birt Hogg Dube Syndrome and their family members of any
age will be recruited from the dermatology, urology, oncology, and genetics communities
worldwide.
Patients with at least one histologically confirmed fibrofolliculomas; or
Patients with clinical evidence of multiple skin papules (without fibrofolliculoma biopsy
confirmation) and a personal or family history of spontaneous pneumothorax / or kidney
cancer; or
Patients with spontaneous pneumothorax and skin papules or kidney cancer and a positive
family history of spontaneous pneumothorax, skin papules or kidney cancer; or
A relative of a patient with a confirmed diagnosis of BHD, or
Renal tumor histology consistent with BHD, including, but not limited to those suggestive
of chromophobe, oncocytic neoplasm oroncocytoma.
EXCLUSION CRITERIA:
Persons unable to give informed consent.
|
| NCT ID: |
|
NCT00033137 |
| Primary Contact: |
|
Principal Investigator
W. Marston Linehan, M.D.
National Cancer Institute (NCI)
W. Marston Linehan, M.D.
Phone: (301) 496-6353
Email: linehanm@mail.nih.gov
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Bethesda, Maryland 20892
United States
For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
Phone: (888) NCI-1937
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|